(CercleFinance.com) – Sanofi announces the signing of a collaboration agreement with Janssen Pharmaceuticals, a Johnson & Johnson company, to develop and commercialize the vaccine candidate against extraintestinal pathogenic E.coli (9-valent) ( ExPEC9V).
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis, causing approximately 10 million cases of ExPEC disease per year worldwide.
Thomas Triomphe, Executive Vice President, Vaccines, Sanofi ‘At Sanofi, we believe in the power of partnership to create true innovation. In this case, we bring together Janssen’s strong science and Sanofi’s global industrial footprint and expertise in launching innovative vaccines. We look forward to delivering this first-in-class vaccine designed to help older people around the world live longer, healthier lives.’